Lapatinib Ditosylate Monohydratorum CAS 388082-78-8 Puritas >99.0% (HPLC)

Description:

Chemical Name: Lapatinib Ditosylate Monohydrate

CAS: 388082-78-8

Puritas: >99.0% (HPLC)

Aspectus: Pallida ad Yellow Crystallina pulveris

Contactus: Dr

Mobile/Wechat/Whatsapp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Lapatinib intermedia:

Lapatinib Base	CAS 231277-92-2
Lapatinib Ditosylate Monohydrate	CAS 388082-78-8
Sodium Methanesulfinate	CAS 20277-69-4
3-Chloro-4-(3-Fluorobenzyloxy)aniline	CAS 202197-26-0
2-Aminoethyl Methyl Sulfone Hydrochloridis	CAS 104458-24-4
4-Chloro-6-Iodoquinazoline	CAS 98556-31-1
6-Iodo-4-Hydroxyquinazoline	CAS 16064-08-7
5-Formyl-2-Acidi Furanboronic	CAS 27329-70-0
5-[4-[3-Chloro-4-(3-Fluorobenzyloxy)anilino]-6-Quinazolinyl]furan-2-Carboxaldehyde	CAS 231278-84-5

Chemical Properties:

Nomen chemicum	Lapatinib Ditosylate Monohydrate
Synonyma	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
CAS Number	388082-78-8
Stock Status	In Stock
Formulae hypotheticae	C29H26ClFN4O4S·2(C7H8O3S)·H2O
M. Pondus	943.48
COA & MSDS	Praesto
Origin	Shanghai, China
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Pallida ad Yellow Crystallina pulveris
Puritas / Analysis Methodus	≥99.0% (HPLC)
Liquescens punctum	240.0~242.0℃
Humor (KF)	1.9~2.4%
una immunditia	≤0.50%
Totalis immunditias	≤1.00%
Metalla gravia (ut Pb)	≤20ppm
Test Standard	Enterprise Standard
Consuetudinem	API;Ad curationem aegris cum carcinomate

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris

Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine et humore

commoda:

FAQ:

388082-78-8 - Applicatio:

Ditosylatus monohydratus (CAS: 388082-78-8) est sal ditosylatum.CAS 231277-92-2synthetica, viva quinazoline ore-activa cum actu antineoplastico potentiali.Reverse impedit phosphorylationem incrementi epidermalis factoris receptoris (EGFR), ErbB2, et Erk-1 et-2 et kinases AKT;etiam vetat cyclinum D aequationes dapibus in humano tumore cellularum linearum et xenografts.EGFR et ErbB2 variis tumoris generibus incrementum implicatae sunt.Curatio provectioris metastaticae HER2 (ErbB2) positivo carcinomate pectoris positivo in feminis quae therapiam prior accepit.Medicamentum a GlaxoSmithKline inventum et elaboratum.